Elizabeth Silbermann1, Lindsey Wooliscroft2,3, Dennis Bourdette2. 1. Department of Neurology, Oregon Health & Science University, Mail code: L226, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239, USA. silberme@ohsu.edu. 2. Department of Neurology, Oregon Health & Science University, Mail code: L226, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239, USA. 3. Department of Veterans Affairs Portland Health Care System, Portland, OR, 97239, USA.
Abstract
PURPOSE OF REVIEW: Clinical trials using agents directed at neuroprotection and remyelination in multiple sclerosis (MS) are needed. As optic neuritis (ON) is common in people with MS and the pathology of ON is similar to other MS lesions in the brain, measurements of the anterior visual system are frequently utilized in neuroprotection and remyelination trials. Understanding the strengths and weaknesses of the measurements is vital when interpreting the results of this research. RECENT FINDINGS: Techniques such as visual evoked potentials (VEP) and optical coherence tomography (OCT) are well established in MS and are thought to measure axonal integrity and myelination. Novel imaging techniques can also be used in conjunction with these measurements to provide better insight into optic nerve structure and function. Magnetization transfer imaging (MTR) together with optic nerve area and volume measures neurodegeneration; diffusion tensor imaging (DTI) measures myelination status and neurodegeneration. However, these techniques require various levels of experience to interpret, and all can be confounded by ocular motion and surrounding fat and bone. This article provides a review of established and novel techniques to measure the anterior visual system in multiple sclerosis with a focus on the evidence to support their use as outcome measures in clinical trials focused on neuroprotection and remyelination therapies.
PURPOSE OF REVIEW: Clinical trials using agents directed at neuroprotection and remyelination in multiple sclerosis (MS) are needed. As optic neuritis (ON) is common in people with MS and the pathology of ON is similar to other MS lesions in the brain, measurements of the anterior visual system are frequently utilized in neuroprotection and remyelination trials. Understanding the strengths and weaknesses of the measurements is vital when interpreting the results of this research. RECENT FINDINGS: Techniques such as visual evoked potentials (VEP) and optical coherence tomography (OCT) are well established in MS and are thought to measure axonal integrity and myelination. Novel imaging techniques can also be used in conjunction with these measurements to provide better insight into optic nerve structure and function. Magnetization transfer imaging (MTR) together with optic nerve area and volume measures neurodegeneration; diffusion tensor imaging (DTI) measures myelination status and neurodegeneration. However, these techniques require various levels of experience to interpret, and all can be confounded by ocular motion and surrounding fat and bone. This article provides a review of established and novel techniques to measure the anterior visual system in multiple sclerosis with a focus on the evidence to support their use as outcome measures in clinical trials focused on neuroprotection and remyelination therapies.
Authors: Elizabeth C Graham; Yuyi You; Con Yiannikas; Raymond Garrick; John Parratt; Michael H Barnett; Alexander Klistorner Journal: Invest Ophthalmol Vis Sci Date: 2016-04-01 Impact factor: 4.799
Authors: Kurt-Wolfram Sühs; Katharina Hein; Muriel B Sättler; Anke Görlitz; Christoph Ciupka; Kerstin Scholz; Barbara Käsmann-Kellner; Panagiotis Papanagiotou; Nina Schäffler; Cordula Restemeyer; Diana Bittersohl; Andrea Hassenstein; Berthold Seitz; Wolfgang Reith; Klaus Fassbender; Reinhard Hilgers; Christoph Heesen; Mathias Bähr; Ricarda Diem Journal: Ann Neurol Date: 2012-08 Impact factor: 10.422
Authors: Rhian Raftopoulos; Simon J Hickman; Ahmed Toosy; Basil Sharrack; Shahrukh Mallik; David Paling; Daniel R Altmann; Marios C Yiannakas; Prasad Malladi; Rose Sheridan; Ptolemaios G Sarrigiannis; Nigel Hoggard; Martin Koltzenburg; Claudia A M Gandini Wheeler-Kingshott; Klaus Schmierer; Gavin Giovannoni; David H Miller; Raju Kapoor Journal: Lancet Neurol Date: 2016-01-26 Impact factor: 44.182
Authors: Christian Albert; Janine Mikolajczak; Anja Liekfeld; Sophie K Piper; Michael Scheel; Hanna G Zimmermann; Claus Nowak; Jan Dörr; Judith Bellmann-Strobl; Claudia Chien; Alexander U Brandt; Friedemann Paul; Olaf Hoffmann Journal: BMC Neurol Date: 2020-03-03 Impact factor: 2.474
Authors: Rocío Benítez-Fernández; Carolina Melero-Jerez; Carmen Gil; Enrique J de la Rosa; Ana Martínez; Fernando de Castro Journal: Int J Mol Sci Date: 2021-02-28 Impact factor: 5.923